Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Kidney International|May 9, 2018
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effectiveLaurent Alric, Isabelle Ollivier-Hourmand, Emilie Bérard, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2020
Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patientsThomas Mouillot, Maud Rizk, Jean-Paul Pais de Barros, et al.
Journal of Clinical Gastroenterology|August 9, 2017
Albumin Use in Patients With Cirrhosis in France: Results of the "ALBU-LIVE" Survey: A Case for Better EASL Guidelines Diffusion and/or RevisionArmand Garioud, Jean-François Cadranel, Arnaud Pauwels, et al.
Arthritis Care & Research|February 26, 2013
Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseasesNina Droz, Laurent Gilardin, Patrice Cacoub, et al.
Journal of Hepatology|July 3, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV statusEtienne Audureau, Fabrice Carrat, Richard Layese, et al.
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
Pageof 4